Literature DB >> 16206115

Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain.

Carmen de Mendoza1, Carmen Rodriguez, Javier Colomina, Concepcion Tuset, Federico Garcia, Jose M Eiros, Angelica Corral, Pilar Leiva, Jesus Aguero, Julian Torre-Cisneros, Jose Pedreira, Isabel Viciana, Jorge del Romero, Ana Saez, Raul Ortiz de Lejarazu, Vincent Soriano.   

Abstract

The prevalence of drug resistance mutations was 12.1% among 198 persons who experienced human immunodeficiency virus (HIV) seroconversion identified in Spain during 1997-2004. There was a significant increase of K103N and of non-B subtypes over time. Transmission of HIV infection around the time of seroconversion was shown in 8 couples and in 2 clusters of 3 individuals.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16206115     DOI： 10.1086/496982

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Authors:  Sonya J Snedecor; Lavanya Sudharshan; Katherine Nedrow; Abhijeet Bhanegaonkar; Kit N Simpson; Seema Haider; Richard Chambers; Charles Craig; Jennifer Stephens
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

2.  Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

Authors:  Fenglei Huang; Michael Koenen-Bergmann; Thomas R Macgregor; Arne Ring; Susan Hattox; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

3.  Origin and epidemiological history of HIV-1 CRF14_BG.

Authors:  Inês Bártolo; Ana B Abecasis; Pedro Borrego; Helena Barroso; Francine McCutchan; Perpétua Gomes; Ricardo Camacho; Nuno Taveira
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

4.  Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

Authors:  Gonzalo Yebra; Miguel de Mulder; María Jesús Pérez-Elías; José Antonio Pérez-Molina; Juan Carlos Galán; Jara Llenas-García; Santiago Moreno; África Holguín
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

5.  Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Authors:  Juan Ambrosioni; Omar Sued; David Nicolas; Marta Parera; María López-Diéguez; Anabel Romero; Fernando Agüero; María Ángeles Marcos; Christian Manzardo; Laura Zamora; Manuel Gómez-Carrillo; José María Gatell; Tomás Pumarola; José María Miró
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

6.  Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations.

Authors:  Yolanda Vega; Elena Delgado; Aurora Fernández-García; Maria Teresa Cuevas; Michael M Thomson; Vanessa Montero; Monica Sánchez; Ana Maria Sánchez; Lucia Pérez-Álvarez
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

7.  The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients.

Authors:  Sonya J Snedecor; Alexandra Khachatryan; Katherine Nedrow; Richard Chambers; Congyu Li; Seema Haider; Jennifer Stephens
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

8.  First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study.

Authors:  Fabia Zu Knyphausen; Ramona Scheufele; Claudia Kücherer; Klaus Jansen; Sybille Somogyi; Stephan Dupke; Heiko Jessen; Dirk Schürmann; Osamah Hamouda; Karolin Meixenberger; Barbara Bartmeyer
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.